IR-Center Handelsblatt

Tiancheng Pharmaceutical Holdings AG

News Detail

DGAP-News News vom 07.07.2017

Tiancheng Pharmaceutical Holdings AG: Successful completion of additional acceptance period

DGAP-News: Tiancheng Pharmaceutical Holdings AG / Key word(s): Offer

07.07.2017 / 11:32
The issuer is solely responsible for the content of this announcement.


Successful completion of additional acceptance period

Munich, 7 July 2017 - Tiancheng (Germany) Pharmaceutical Holdings AG, a company indirectly controlled by Creat Group Corporation, ("Bidder"), today announced that, after termination of the additional acceptance period on 4 July 2017, the offer has been accepted for a total of 17,783,776 Biotest ordinary shares, corresponding to 89.88% of the voting share capital and 44.94% of the total share capital of Biotest AG ("Biotest") and for 214,581 Biotest preference shares, corresponding to 0.54% of the total share capital of Biotest.

Mr Wu Xu, CEO of Creat, said: "We are delighted and highly motivated by the strong confidence that Biotest shareholders have placed in our offer. With the additional acceptance period having been completed successfully, and once the relevant regulatory approvals have been granted, we will focus on delivering immediate value for all stakeholders. We look forward to supporting the Biotest team with their business plan and thus laying the ground for a promising future for Biotest."

Dr. Bernhard Ehmer, Chairman of Biotest's Board of Management, said: "We are pleased that such a large majority of Biotest shareholders have followed our clear recommendation and accepted the offer. We believe that with Creat on board, we will be ideally placed to enhance our competitiveness going forward."

The completion of the offer remains subject to foreign investment control and merger control approvals. Merger control approval in the United States has already been granted.

About Creat Group Corporation
Creat Group Corporation ( is a leading Chinese investment group founded in 1992 that has significant expertise in the plasma industry. It invests in healthcare and pharmaceuticals, manufacturing, energy, finance, and natural resources. The company is based in Beijing, China, with other offices in Hong Kong and Shanghai. Through its investment in China's largest listed blood products company Shanghai RAAS as well as the 2016 acquisition of UK-based plasma supplier and manufacturer of plasma-derived protein therapeutics Bio Products Laboratory, Creat is a significant investor in the global plasma market.

Important Notice
This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Biotest. The definite terms and conditions of the takeover offer, as well as further provisions concerning the takeover offer, have been published in the offer document following approval by the German Federal Financial Supervisory Authority. Investors and holders of shares in Biotest are strongly advised to read the offer document and all other relevant documents regarding the takeover offer, since they contain important information.
The takeover offer has been issued exclusively under the laws of the Federal Republic of Germany and certain applicable provisions of U.S. securities law. Any contract that is concluded on the basis of the takeover offer is exclusively governed by the laws of the Federal Republic of Germany and is to be interpreted in accordance with such laws.

Media Contact
Knut Engelmann
CNC - Communications & Network Consulting AG
T +49 69 506 037 570

07.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this